MonTa Bisciences have in January opened additionally 4 clinical sites in Madrid and Bruxelles. We have since Q2, 2021 dosed patients in our dose-escalation phase I study at two sites in Denmark, and are now expanding number of sites to six in order to be prepared for moving into the expansion cohort with recruitment of at least 24 patients.
